SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures
Identifieur interne : 000B14 ( Pmc/Corpus ); précédent : 000B13; suivant : 000B15SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures
Auteurs : Priya Sampathkumar ; Zelalem Temesgen ; Thomas F. Smith ; Rodney L. ThompsonSource :
- Mayo Clinic Proceedings [ 0025-6196 ] ; 2003.
Abstract
Severe acute respiratory syndrome (SARS) is a recently recognized febrile respiratory illness that first appeared in southern China in November 2002, has since spread to several countries, and has resulted in more than 8000 cases and more than 750 deaths. The disease has been etiologically linked to a novel coronavirus that has been named the
Url:
DOI: 10.4065/78.7.882
PubMed: 12839084
PubMed Central: 7094524
Links to Exploration step
PMC:7094524Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures</title><author><name sortKey="Sampathkumar, Priya" sort="Sampathkumar, Priya" uniqKey="Sampathkumar P" first="Priya" last="Sampathkumar">Priya Sampathkumar</name><affiliation><nlm:aff id="aff1">Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</nlm:aff></affiliation></author><author><name sortKey="Temesgen, Zelalem" sort="Temesgen, Zelalem" uniqKey="Temesgen Z" first="Zelalem" last="Temesgen">Zelalem Temesgen</name><affiliation><nlm:aff id="aff1">Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</nlm:aff></affiliation></author><author><name sortKey="Smith, Thomas F" sort="Smith, Thomas F" uniqKey="Smith T" first="Thomas F." last="Smith">Thomas F. Smith</name><affiliation><nlm:aff id="aff2">Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn.</nlm:aff></affiliation></author><author><name sortKey="Thompson, Rodney L" sort="Thompson, Rodney L" uniqKey="Thompson R" first="Rodney L." last="Thompson">Rodney L. Thompson</name><affiliation><nlm:aff id="aff1">Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">12839084</idno><idno type="pmc">7094524</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094524</idno><idno type="RBID">PMC:7094524</idno><idno type="doi">10.4065/78.7.882</idno><date when="2003">2003</date><idno type="wicri:Area/Pmc/Corpus">000B14</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B14</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures</title><author><name sortKey="Sampathkumar, Priya" sort="Sampathkumar, Priya" uniqKey="Sampathkumar P" first="Priya" last="Sampathkumar">Priya Sampathkumar</name><affiliation><nlm:aff id="aff1">Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</nlm:aff></affiliation></author><author><name sortKey="Temesgen, Zelalem" sort="Temesgen, Zelalem" uniqKey="Temesgen Z" first="Zelalem" last="Temesgen">Zelalem Temesgen</name><affiliation><nlm:aff id="aff1">Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</nlm:aff></affiliation></author><author><name sortKey="Smith, Thomas F" sort="Smith, Thomas F" uniqKey="Smith T" first="Thomas F." last="Smith">Thomas F. Smith</name><affiliation><nlm:aff id="aff2">Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn.</nlm:aff></affiliation></author><author><name sortKey="Thompson, Rodney L" sort="Thompson, Rodney L" uniqKey="Thompson R" first="Rodney L." last="Thompson">Rodney L. Thompson</name><affiliation><nlm:aff id="aff1">Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</nlm:aff></affiliation></author></analytic><series><title level="j">Mayo Clinic Proceedings</title><idno type="ISSN">0025-6196</idno><idno type="eISSN">1942-5546</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Severe acute respiratory syndrome (SARS) is a recently recognized febrile respiratory illness that first appeared in southern China in November 2002, has since spread to several countries, and has resulted in more than 8000 cases and more than 750 deaths. The disease has been etiologically linked to a novel coronavirus that has been named the <italic>SARS-associated coronavirus</italic>. It appears to be spread primarily by large droplet transmission. There is no specific therapy, and management consists of supportive care. This article summarizes currently available information regarding the epidemiology, clinical features, etiologic agent, and modes of transmission of the disease, as well as infection control measures appropriate to contain SARS.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="World Health Organization" uniqKey="World Health Organization">World Health Organization</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centers For Disease Control And Prevention" uniqKey="Centers For Disease Control And Prevention">Centers for Disease Control and Prevention</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centers For Disease Control And Prevention" uniqKey="Centers For Disease Control And Prevention">Centers for Disease Control and Prevention</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centers For Disease Control And Prevention" uniqKey="Centers For Disease Control And Prevention">Centers for Disease Control and Prevention</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poutanen, Sm" uniqKey="Poutanen S">SM Poutanen</name></author><author><name sortKey="Low, De" uniqKey="Low D">DE Low</name></author><author><name sortKey="Henry, B" uniqKey="Henry B">B Henry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hsu, L Y" uniqKey="Hsu L">L-Y Hsu</name></author><author><name sortKey="Lee, C C" uniqKey="Lee C">C-C Lee</name></author><author><name sortKey="Green, Ja" uniqKey="Green J">JA Green</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Booth, Cm" uniqKey="Booth C">CM Booth</name></author><author><name sortKey="Matukas, Lm" uniqKey="Matukas L">LM Matukas</name></author><author><name sortKey="Tomlinson, Ga" uniqKey="Tomlinson G">GA Tomlinson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, Jsm" uniqKey="Peiris J">JSM Peiris</name></author><author><name sortKey="Chu, Cm" uniqKey="Chu C">CM Chu</name></author><author><name sortKey="Cheng, Vcc" uniqKey="Cheng V">VCC Cheng</name></author><author><name sortKey="Hku Uch Sars Study Group" uniqKey="Hku Uch Sars Study Group">HKU/UCH SARS Study Group</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hon, Kle" uniqKey="Hon K">KLE Hon</name></author><author><name sortKey="Leung, Cw" uniqKey="Leung C">CW Leung</name></author><author><name sortKey="Cheng, Wtf" uniqKey="Cheng W">WTF Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, N" uniqKey="Lee N">N Lee</name></author><author><name sortKey="Hui, D" uniqKey="Hui D">D Hui</name></author><author><name sortKey="Wu, A" uniqKey="Wu A">A Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, Jsm" uniqKey="Peiris J">JSM Peiris</name></author><author><name sortKey="Lai, St" uniqKey="Lai S">ST Lai</name></author><author><name sortKey="Poon, Ll" uniqKey="Poon L">LL Poon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C Drosten</name></author><author><name sortKey="Gunther, S" uniqKey="Gunther S">S Günther</name></author><author><name sortKey="Preiser, W" uniqKey="Preiser W">W Preiser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ksiazek, Tg" uniqKey="Ksiazek T">TG Ksiazek</name></author><author><name sortKey="Erdman, D" uniqKey="Erdman D">D Erdman</name></author><author><name sortKey="Goldsmith, Cs" uniqKey="Goldsmith C">CS Goldsmith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marra, Ma" uniqKey="Marra M">MA Marra</name></author><author><name sortKey="Jones, Sjm" uniqKey="Jones S">SJM Jones</name></author><author><name sortKey="Astell, Cr" uniqKey="Astell C">CR Astell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rota, Pa" uniqKey="Rota P">PA Rota</name></author><author><name sortKey="Oberste, Ms" uniqKey="Oberste M">MS Oberste</name></author><author><name sortKey="Monroe, Ss" uniqKey="Monroe S">SS Monroe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="World Health Organization" uniqKey="World Health Organization">World Health Organization</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centers For Disease Control And Prevention" uniqKey="Centers For Disease Control And Prevention">Centers for Disease Control and Prevention</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centers For Disease Control And Prevention" uniqKey="Centers For Disease Control And Prevention">Centers for Disease Control and Prevention</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Centers For Disease Control And Prevention" uniqKey="Centers For Disease Control And Prevention">Centers for Disease Control and Prevention</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="So, Lk" uniqKey="So L">LK So</name></author><author><name sortKey="Lau, Ac" uniqKey="Lau A">AC Lau</name></author><author><name sortKey="Yam, Ly" uniqKey="Yam L">LY Yam</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Mayo Clin Proc</journal-id><journal-id journal-id-type="iso-abbrev">Mayo Clin. Proc</journal-id><journal-title-group><journal-title>Mayo Clinic Proceedings</journal-title></journal-title-group><issn pub-type="ppub">0025-6196</issn><issn pub-type="epub">1942-5546</issn><publisher><publisher-name>Mayo Foundation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12839084</article-id><article-id pub-id-type="pmc">7094524</article-id><article-id pub-id-type="publisher-id">S0025-6196(11)62689-X</article-id><article-id pub-id-type="doi">10.4065/78.7.882</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sampathkumar</surname><given-names>Priya</given-names></name><degrees>MD</degrees><email>sampathkumar.priya@mayo.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Temesgen</surname><given-names>Zelalem</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Thomas F.</given-names></name><degrees>PHD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Rodney L.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Division of Infectious Diseases and Internal Medicine, Rochester, Minn.</aff><aff id="aff2"><label>b</label>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn.</aff><author-notes><corresp id="cor1"><label>*</label>Address reprint requests and correspondence to Priya Sampathkumar, MD, Division of Infectious Diseases, Mayo Clinic, 200 First St Sw, Rochester, MN 55905 <email>sampathkumar.priya@mayo.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>20</day><month>10</month><year>2011</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>7</month><year>2003</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2011</year></pub-date><volume>78</volume><issue>7</issue><fpage>882</fpage><lpage>890</lpage><permissions><copyright-statement>Copyright © 2003 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2003</copyright-year><copyright-holder>Mayo Foundation for Medical Education and Research</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><related-article related-article-type="article-reference" id="d32e385" ext-link-type="doi" xlink:href="10.4065/78.7.813"></related-article><abstract><p>Severe acute respiratory syndrome (SARS) is a recently recognized febrile respiratory illness that first appeared in southern China in November 2002, has since spread to several countries, and has resulted in more than 8000 cases and more than 750 deaths. The disease has been etiologically linked to a novel coronavirus that has been named the <italic>SARS-associated coronavirus</italic>. It appears to be spread primarily by large droplet transmission. There is no specific therapy, and management consists of supportive care. This article summarizes currently available information regarding the epidemiology, clinical features, etiologic agent, and modes of transmission of the disease, as well as infection control measures appropriate to contain SARS.</p></abstract><kwd-group><kwd>ARDS, acute respiratory distress syndrome</kwd><kwd>CDC, Centers for Disease Control and Prevention</kwd><kwd>CT, computed tomography</kwd><kwd>HCWs, health care workers</kwd><kwd>RT-PCR, reverse-transcriptase polymerase chain reaction</kwd><kwd>SARS, severe acute respiratory syndrome</kwd><kwd>SARS-CoV, SARS coronavirus</kwd></kwd-group></article-meta></front><body><p id="para520">Severe acute respiratory syndrome (SARS) is the first important new infectious disease of the new millennium. It is now believed that the disease is caused by a novel coronavirus (SARS-CoV). SARS was first recognized as a distinct entity in February 2003 by Dr Carlo Urbani, an epidemiologist with the World Health Organization who was investigating the outbreak in Hanoi, Vietnam. Unfortunately, he himself contracted the disease and died. Since then and up to June 5, 2003, the disease has spread to affect more than 8000 worldwide.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Although the medical community at large has been aware of this disease for only a few months, considerable progress has been made in understanding the epidemiology and clinical features, and the etiologic agent has been identified.</p><sec id="cesec10"><title>EPIDEMIOLOGY</title><p id="para530">A highly contagious atypical pneumonia first appeared in the Guangdong Province, People's Republic of China, in November 2002. This was not widely publicized, and the condition remained isolated to China for the next 3 months. On February 21, 2003, a Chinese physician from the Guangdong Province (patient A in <xref rid="fig1" ref-type="fig">Figure 1</xref>) who cared for patients with pneumonia and had himself developed symptoms traveled to Hong Kong to visit relatives. He stayed on the ninth floor of Hotel M for a day. On February 22, 2003, he was admitted to Hospital 2 with fever and respiratory symptoms and died of respiratory failure on March 4, 2003. He infected 2 of his family members and 4 health care workers (HCWs) in Hospital 2. In addition, 12 other hotel guests at Hotel M developed SARS, 10 of whom (patients B through K) were in the hotel the same day as patient A; the other 2 patients (patients L and M) stayed in the hotel during the time that 3 other symptomatic patients were guests at the hotel. Because of international travel and transmission to HCWs before the institution of protective measures, these patients were responsible for subsequent clusters of SARS around the globe. Patient B was the index patient for the outbreak in Hanoi involving HCWs and close contacts, including Dr Urbani. Patients C, D, and E were the index cases in Singapore. Patients F and G traveled back to Toronto, Canada, which resulted in the cluster of cases in Toronto. Patients H and J caused outbreaks among HCWs in other hospitals in Hong Kong. Patient L appears to have become infected during his stay at Hotel M, with subsequent transmission to his wife, patient M in the United States (<xref rid="fig1" ref-type="fig">Figure 1</xref>).<fig id="fig1"><label>Figure 1</label><caption><p>Chain of transmission of severe acute respiratory syndrome from the initial patient to other guests at Hotel M in Hong Kong in 2003.</p><p>*All guests except G and K stayed on the ninth floor of the hotel. Guest G stayed on the 14th floor, and guest K stayed on the 11th floor.</p><p>†Guests L and M (spouses) were not at Hotel M during the same time as index guest A but were at the hotel during the same times as guests G and H and were ill during this period. HCWs = health care workers. From the Centers for Disease Control and Prevention.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p></caption><graphic xlink:href="gr1"></graphic></fig></p><p id="para540">Aggressive and unprecedented measures that included quarantine of thousands of people, travel restrictions, and temperature checks at airports have been successful to a large extent in containing the disease. Vietnam reported its last case more than 30 days ago. Singapore used its military forces to assist in contact tracing and enforcement of home quarantine. Through this and other measures, including screening of passengers at airports and seaports, concentration of patients in a single SARS-designated hospital, imposition of a no-visitors rule for all public hospitals, and use of a dedicated private ambulance service to transport all possible cases to the SARS-designated hospital, Singapore may have successfully controlled its outbreak and reported its last case on May 11, 2003. Hong Kong instituted a program of intensive contact tracing and home quarantine of all contacts and has reported a substantial decline in the number of new cases. Authorities in Toronto initially appeared to have controlled their outbreak, but on May 22, Health Canada began to report new clusters of cases of SARS, and since then 70 new cases linked to 4 Toronto hospitals have been reported. Mainland China and Taiwan continue to report new cases, and there is ongoing community transmission, although the daily number of reported new probable cases of SARS has declined from a mean of 166 cases during the first week of May to a mean of 2.5 cases in the first week of June.</p><p id="para550">Reported cases in all other countries have acquired infection through travel to endemic areas, and only limited local transmission through close contact has occurred. As of June 3, 2003, a total of 372 cases have been reported in the United States (303 suspect and 69 probable cases, no deaths), and almost all the patients acquired infection while traveling overseas.</p></sec><sec id="cesec20"><title>CASE DEFINITION</title><p id="para560">Based on available data, the Centers for Disease Control and Prevention (CDC) defines a <italic>suspect case</italic> of SARS as a person with onset of fever (temperature >38°C [100.4°F]) and lower respiratory tract symptoms within 10 days of either travel to an area with documented transmission of SARS or close contact with a person believed to have SARS. A <italic>probable case</italic> is a suspect case who also has chest radiographic findings of pneumonia, acute respiratory distress syndrome (ARDS), or an unexplained respiratory illness resulting in death, with autopsy findings of ARDS without identifiable cause.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Suspect and probable cases are further classified based on laboratory findings as <italic>laboratory positive, laboratory negative</italic>, or <italic>indeterminate</italic> (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Centers for Disease Control and Prevention Case Definition for SARS<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref><xref rid="tbl1fn1" ref-type="table-fn">*</xref></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><list list-type="simple" id="celist10"><list-item id="celistitem10"><p id="para10">Clinical criteria
<list list-type="simple" id="celist20"><list-item id="celistitem20"><p id="para20">Asymptomatic or mild respiratory illness</p></list-item><list-item id="celistitem30"><p id="para30">Moderate respiratory illness
<list list-type="simple" id="celist30"><list-item id="celistitem40"><p id="para40">Temperature >100.4°F (>38°C) <bold><italic>and</italic></bold></p></list-item><list-item id="celistitem50"><p id="para50">One or more clinical findings of respiratory illness (eg, cough, shortness of breath, difficulty with breathing, or hypoxia)</p></list-item></list></p></list-item><list-item id="celistitem60"><p id="para60">Severe respiratory illness
<list list-type="simple" id="celist40"><list-item id="celistitem70"><p id="para70">Temperature >100.4°F (>38°C) <bold><italic>and</italic></bold></p></list-item><list-item id="celistitem80"><p id="para80">One or more clinical findings of respiratory illness (eg, cough, shortness of breath, difficulty with breathing, or hypoxia)</p></list-item><list-item id="celistitem90"><p id="para90"><bold>AND</bold></p></list-item><list-item id="celistitem100"><p id="para100">Radiographic evidence of pneumonia <bold><italic>or</italic></bold></p></list-item><list-item id="celistitem110"><p id="para110">ARDS <bold><italic>or</italic></bold></p></list-item><list-item id="celistitem120"><p id="para120">Autopsy findings consistent with pneumonia or ARDS without an identifiable cause</p></list-item></list></p></list-item></list></p></list-item><list-item id="celistitem130"><p id="para130">Epidemiological criteria
<list list-type="simple" id="celist50"><list-item id="celistitem140"><p id="para140">Travel (including transit in an airport) within 10 days of onset of symptoms to an area with current or recently documented or suspected community transmission of SARS<xref rid="tbl1fn2" ref-type="table-fn">†</xref></p></list-item><list-item id="celistitem150"><p id="para150"><bold>OR</bold></p></list-item><list-item id="celistitem160"><p id="para160">Close contact within 10 days of onset of symptoms with a person known or suspected to have SARS infection</p></list-item></list></p></list-item><list-item id="celistitem170"><p id="para170">Laboratory criteria
<list list-type="simple" id="celist60"><list-item id="celistitem180"><p id="para180">Confirmed
<list list-type="simple" id="celist70"><list-item id="celistitem190"><p id="para190">Detection of antibody to SARS-CoV in specimens obtained during acute illness or >21 days after illness onset <bold><italic>or</italic></bold></p></list-item><list-item id="celistitem200"><p id="para200">Detection of SARS-CoV RNA by RT-PCR confirmed by a second</p></list-item><list-item id="celistitem210"><p id="para210">PCR assay, by using a second aliquot of the specimen and a different set of PCR primers <bold><italic>or</italic></bold></p></list-item><list-item id="celistitem220"><p id="para220">Isolation of SARS-CoV</p></list-item></list></p></list-item><list-item id="celistitem230"><p id="para230">Negative
<list list-type="simple" id="celist80"><list-item id="celistitem240"><p id="para240">Absence of antibody to SARS-CoV in convalescent serum obtained >21 days after symptom onset</p></list-item></list></p></list-item><list-item id="celistitem250"><p id="para250">Undetermined
<list list-type="simple" id="celist90"><list-item id="celistitem260"><p id="para260">Laboratory testing either not performed or incomplete</p></list-item></list></p></list-item></list></p></list-item><list-item id="celistitem270"><p id="para270">Case classification
<list list-type="simple" id="celist100"><list-item id="celistitem280"><p id="para280">Probable case
<list list-type="simple" id="celist110"><list-item id="celistitem290"><p id="para290">Meets the clinical criteria for severe respiratory illness of unknown etiology with onset since November 1, 2002, and epidemiological criteria; laboratory criteria confirmed, negative, or undetermined</p></list-item></list></p></list-item><list-item id="celistitem300"><p id="para300">Suspect case
<list list-type="simple" id="celist120"><list-item id="celistitem310"><p id="para310">Meets the clinical criteria for moderate respiratory illness of unknown etiology with onset since November 1, 2002, and epidemiological criteria; laboratory criteria confirmed, negative, or undetermined</p></list-item></list></p></list-item></list></p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn id="tbl1fn1"><label>*</label><p>ARDS = acute respiratory distress syndrome; RT-PCR = reverse-transcriptase polymerase chain reaction; SARS = severe acute respiratory syndrome; SARS-CoV = SARS coronavirus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn2"><label>†</label><p>Travel criteria for suspect or probable US cases of SARS. Last date of illness onset for inclusion as a reported case: China (mainland), Hong Kong, Taiwan, Toronto, ongoing; Hanoi, Vietnam, May 25, 2003; Singapore, June 4, 2003.</p></fn></table-wrap-foot></table-wrap></p><p id="para570">It is important to understand the meaning of <italic>close contact</italic>. It is defined as having cared for or lived with a person known to have SARS or unprotected contact with body secretions from such a person. This includes kissing, embracing, sharing utensils or bedding, performing a physical examination, or other direct physical contact between persons. It does not include sitting across a waiting room for a brief period, walking by a person with SARS, or other casual contact.</p></sec><sec id="cesec30"><title>CLINICAL FEATURES</title><p id="para580">The incubation period is 2 to 10 days. Early manifestations include influenza-like symptoms, such as fever, myalgias, and headache. Fever occurs in virtually all patients and is often the presenting symptom. Often, fever is high and sometimes associated with chills and rigors. Fever may occasionally be absent in elderly persons or may have resolved by the time respiratory symptoms occur. Typically, rash and neurologic findings are absent. Diarrhea has been reported in up to 25% of patients.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> The respiratory phase starts within 2 to 4 days of onset of fever with a dry, nonproductive cough. This may progress to shortness of breath, usually in the second week of the illness, and might be accompanied by or progress to hypoxemia. In 10% to 20% of patients, the respiratory illness is severe enough to require tracheal intubation and mechanical ventilation. The case fatality rate is approximately 3% to 12% overall. The mortality rate may be as high as 45% in patients older than 60 years, particularly those with preexisting comorbidity (eg, diabetes, renal failure, and other chronic medical conditions).<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> A concerning feature of this disease has been that young, previously healthy persons, many of them health care professionals, have also died of SARS. The reason for this is unclear but may be due to exposure to patients with higher viral loads or due to their host response. In contrast, SARS has affected relatively few children and appears to be milder in the pediatric age group.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p><p id="para590">A biphasic course has been described in many patients, with an initial illness followed by improvement and then subsequent deterioration. This worsening can present as recurrent fever 4 to 7 days after initial defervescence, new chest infiltrates, respiratory failure, or watery diarrhea. In a cohort of 75 patients in Hong Kong, 85% had recurrent symptoms after initial improvement.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The authors described a triphasic course with fever, myalgia early in week 1, and recurrent fever, hypoxemia, diarrhea, and shifting chest infiltrates in week 2. Twenty percent of patients progressed to ARDS during the third week of the illness. Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal aspirate in 14 patients with relapse showed peak viral loads occurred at day 10 after onset of symptoms, suggesting that the late deterioration may be due to the host immune response rather than to uncontrolled viral replication.</p><sec id="cesec40"><title>Radiology</title><p id="para600">Chest radiographs of patients with SARS show patchy focal infiltrates or consolidation often with a peripheral distribution, which may progress to diffuse infiltrates. Pleural effusions have not been reported. Early findings may be subtle, and initial findings on chest radiographs may be normal in up to 25% of patients.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Computed tomography (CT) may be more sensitive than plain films. Highresolution CT scans have shown abnormalities in patients with suspected SARS who have normal findings on plain films.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The characteristic CT finding is bilateral peripheral airspaceground-glass consolidation mimicking that seen in bronchiolitis obliterans with organizing pneumonia.</p></sec><sec id="cesec50"><title>Laboratory</title><p id="para610">Laboratory findings in patients with SARS include thrombocytopenia and leukopenia (in particular lymphopenia). Elevated creatine kinase, lactate dehydrogenase, and transaminase levels have been noted. A high peak lactate dehydrogenase level and an initial elevated white blood cell count may carry a poor prognosis.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></p></sec></sec><sec id="cesec60"><title>ETIOLOGY</title><p id="para620">The etiologic link of a coronavirus with the SARS epidemic was established by Peiris et al<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> in Hong Kong. Several diagnostic laboratory methods were used to initially recover and then characterize coronavirus infection in various specimens obtained from patients with SARS. These included inoculation and recovery of the virus in cell cultures, characterization of morphologic features by electron microscopy, serologic antibody determination, and molecular amplification and sequencing of the target RNA of the agent. Overall, 45 of the 50 patients these investigators studied had 1 or more laboratory tests (serology, 32; RT-PCR, 22; culture, 2) that supported a coronavirus etiology. The results of this initial report were quickly confirmed and expanded by collaborative studies in several major public health centers and medical institutions throughout the world coordinated by the World Health Organization.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref> Molecular sequencing analyses have indicated that the virus is only distantly related to previously sequenced coronaviruses. Based on serologic studies, it appears that this virus has not previously circulated in humans and is now referred to as SARS-CoV.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref></p><p id="para630">Coronaviruses are enveloped RNA viruses that cause disease in humans and animals. The previously known human coronaviruses are a major cause of the common cold and can occasionally cause pneumonia. Research teams in Hong Kong and Shenzhen, China, recently detected several coronaviruses closely related genetically to the SARS-CoV in 2 animal species (masked palm civet and raccoon-dog) and antibodies against the SARS-CoV in 1 additional species (Chinese ferret badger). These and other wild animals are traditionally considered delicacies and are sold for human consumption in markets throughout southern China.</p><p id="para640">This study provides the first indication that the SARS-CoV exists outside a human host. Studies are needed to determine how widespread the SARS virus might be in animals in Guangdong and elsewhere and if these animals can excrete the virus in an amount sufficient to infect humans and through what route such transmission occurs.</p></sec><sec id="cesec70"><title>TRANSMISSION</title><p id="para650">The SARS-CoV appears to be transmitted primarily by large droplet spread, although surface contamination and possibly airborne spread may play a role. Recent data suggest that the virus may remain viable for considerable periods on a dry surface (up to 24 hours); hence, transmission through fomites may occur. The outbreak in an apartment complex in Hong Kong that accounted for more than 300 cases has been attributed to fecal spread. A patient with SARS who had diarrhea stayed with his brother in this building. It is thought that infection spread from him to other residents in the building through a leaking sewage drain, which allowed aerosolization of virus-containing material. Sewage also backed into bathroom floor drains in some apartments and may have accounted for some of the transmission. The SARS-CoV is stable in feces (and urine) at room temperature for at least 1 to 2 days. The virus is more stable (up to 4 days) in stool from patients with diarrhea (which has a higher pH than normal stool).<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p><p id="para660">It is presently unclear at what stage of the disease viral shedding occurs or whether someone who is infected but asymptomatic can infect others. As our knowledge of SARS and the etiologic coronavirus evolves, we will be able to address these important issues.</p><p id="para670">Some close contacts have reported a mild febrile illness without respiratory signs or symptoms, suggesting the illness might not always progress to the respiratory phase; others have not become ill at all. In contrast, “super spreaders” have been described who have infected 10 or more contacts, including HCWs, family and social contacts, or visitors to the health care facilities where patients were hospitalized. A similar phenomenon has been described with some other diseases, such as rubella, laryngeal tuberculosis, and Ebola virus, and might be the result of a combination of host, environment, and virus interactions. In Singapore, 5 super spreaders were responsible for a total of 170 suspect and probable cases of SARS.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Additional data on the natural history of infection are needed to understand factors that might be associated with this phenomenon. Regardless of whether it is the result of other transmission routes, inadequate infection-control measures, or more viral shedding by certain patients, the fact remains that transmission of the SARS virus is highly efficient in some circumstances.</p></sec><sec id="cesec80"><title>DIAGNOSIS</title><p id="para680">The initial diagnosis of SARS is one of exclusion. Hence, common causes of respiratory illnesses should be sought. Initial diagnostic testing for patients with suspected SARS should include chest radiography, pulse oximetry, blood cultures, sputum Gram stain and culture, and testing for other respiratory pathogens, notably influenza A and B, respiratory syncytial virus, and <italic>Legionella</italic> (<xref rid="tbl2" ref-type="table">Table 2</xref>). Clinicians should save any available clinical specimens (respiratory, blood, serum, and stool) for additional testing until a specific diagnosis is made.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Diagnostic Approach to Patients With Possible SARS<xref rid="tbl2fn1" ref-type="table-fn">*</xref></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><list list-type="simple" id="celist130"><list-item id="celistitem320"><p id="para320">Chest radiograph</p></list-item><list-item id="celistitem330"><p id="para330">Sputum Gram stain and culture, blood culture</p></list-item><list-item id="celistitem340"><p id="para340">Pulse oximetry</p></list-item><list-item id="celistitem350"><p id="para350">Consider testing for other pathogens such as influenza, respiratory syncytial virus, <italic>Legionella</italic></p></list-item><list-item id="celistitem360"><p id="para360">Save clinical specimens (respiratory, blood, serum, stool) for possible additional testing until a definitive diagnosis is made</p></list-item><list-item id="celistitem370"><p id="para370">Acute and convalescent serum (>21 days after symptom onset)</p></list-item><list-item id="celistitem380"><p id="para380">Contact local and state health departments for SARS-CoV testing</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>*</label><p>SARS = severe acute respiratory syndrome; SARS-CoV = SARS corona-virus.</p></fn></table-wrap-foot></table-wrap></p><p id="para690">Acute and convalescent (>21 days after onset of symptoms) serum samples should be collected from each patient who meets the SARS case definition. Paired sera and other clinical specimens can be forwarded through state and local health departments for testing at the CDC. Specific instructions for collecting specimens from suspected SARS patients are available from the CDC.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Laboratory diagnostic tests used at the CDC to test clinical specimens for evidence of SARS-CoV include serology, PCR testing, and viral cultures.</p><p id="para700">Serologic testing for coronavirus antibody consists of indirect fluorescent antibody testing and enzyme-linked immunosorbent assays that are specific for antibody produced after infection. Patients seem to seroconvert at a mean of 10 days after onset of symptoms. The CDC has made reagents for SARS antibody testing available to state public health laboratories.</p><p id="para710">An RT-PCR test specific for RNA from the SARS-CoV has been positive within the first 10 days after fever onset in respiratory specimens from most patients considered probable cases of SARS who have been tested and in stool samples in the second week of illness. The duration of detectable viremia or viral shedding needs further study.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref></p><p id="para720">Despite the fact that several thousand specimens from patients with SARS have been processed in laboratories worldwide, to date there have been no reported clusters of illness in laboratory workers. Nevertheless, reasonable precautions should be taken in handling these specimens. The CDC recommends that specimens from patients with SARS be labeled accordingly and that the laboratory be alerted before the samples are sent. Laboratory workers who handle these specimens should use standard precautions in a Biosafety Level 2 laboratory. Any procedure with the potential to generate fine particulate aerosols should be performed in a biological safety cabinet.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></p></sec><sec id="cesec90"><title>TREATMENT</title><p id="para730">There is no specific treatment currently available for SARS. Management consists of supportive care and appropriate infection control measures to prevent spread. Because the diagnosis is uncertain, empirical therapy for community-acquired pneumonia should be administered by using antibiotics with activity against both typical and atypical respiratory pathogens including influenza when appropriate. In all series of SARS cases described to date, therapy has involved broad-spectrum antibiotics, including a fluoroquinolone or macrolide. The antiviral drug ribavirin has been used in most patients treated in Hong Kong and in Toronto, without evidence of efficacy.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib10" ref-type="bibr">10</xref> The adverse effects of ribavirin are significant, particularly hemolytic anemia and electrolyte disturbances such as hypokalemia and hypomagnesemia; hence, empirical therapy with ribavirin is not warranted.</p><p id="para740">Anecdotal evidence suggests that corticosteroids may be beneficial, particularly in patients with progressive pulmonary infiltrates and hypoxemia. Various regimens have been used in different centers, with dosages of methylpred-nisolone ranging from 40 mg twice daily (similar to therapy for <italic>Pneumocystis carinii</italic> pneumonia) to 2 mg/kg per day (similar to late-phase therapy for ARDS) to pulse doses of 500 mg intravenously per day.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Because corticosteroids have potential adverse effects, clinicians should carefully assess the risk vs the benefit on a case-by-case basis.</p></sec><sec id="cesec100"><title>INFECTION CONTROL</title><p id="para750">Early recognition and isolation of patients with SARS is key to limiting spread of the disease. Based on our current understanding of disease transmission, infection control measures for suspected SARS cases should include the following.</p><sec id="cesec110"><title>Screening and Triage</title><p id="para760">Early identification of patients with SARS in health care facilities and appropriate isolation are essential in preventing large outbreaks. The CDC has recommended that in health care settings, patients should be screened with targeted questions as soon as possible after arrival or while the patient is on the telephone making an appointment. We have been using a simple screening tool (<xref rid="fig2" ref-type="fig">Figure 2</xref>) to screen all patients in our facility. Patients who have positive findings on the initial screen are given a mask, separated from other patients, placed in an examination room (a negative-air room if available), and evaluated further by a physician with airborne (N-95 respirator) and contact (gown, gloves) precautions. If, during this evaluation, the patient fits the CDC case definition for SARS and needs admission, the patient is admitted to a negative-air room. If admission is unnecessary but further testing is required, the patient is escorted to appropriate areas (for laboratory tests, radiological studies, etc) and testing expedited so that exposure of other patients is minimized.<fig id="fig2"><label>Figure 2</label><caption><p>Screening algorithm used to triage patients at first point of contact.</p><p>*List of affected countries may change; the evaluating physician should check the Centers for Disease Control and Prevention Web site on severe acute respiratory syndrome (SARS) for the most current epidemiological case definition. NIOSH = National Institute of Occupational Safety and Health; TB = tuberculosis.</p></caption><graphic xlink:href="gr2"></graphic></fig></p></sec><sec id="cesec120"><title>Outpatient Setting</title><p id="para770">Diagnosis of SARS does not automatically necessitate admission. Patients who do not otherwise need to be admitted to a hospital should be managed as outpatients as long as they can limit interactions outside the home.</p><p id="para780">Persons being managed as outpatients should be instructed to wear a surgical mask when in the presence of household members, and they should contain respiratory secretions in facial tissue and place these in lined containers for disposal with household waste. They should wash their hands frequently with soap and water or an alcohol-based hand sanitizer, especially after touching respiratory secretions and other body fluids. Sharing of eating utensils, towels, and bedding between patients with SARS and others should be avoided until these items have been washed with soap and hot water. Such patients should stay away from work, school, or other activities in a public place <bold>for 10 days after the resolution of fever</bold> provided that cough and other respiratory symptoms have resolved or have improved. A plan will need to be formulated to decide how these outpatients will obtain food and other supplies such as surgical masks during the period of isolation and how arrangements will be made for travel to and from necessary medical appointments.</p><p id="para790">Household members or other close contacts of patients with SARS should be advised to wear disposable gloves for any direct contact with body fluids from the patient and to practice good hand hygiene. Such people should be vigilant for the development of fever or respiratory symptoms, and if these occur, they should seek health care evaluation. They should inform their health care provider in advance of arriving for the evaluation that they have had close contact with a patient with SARS so that arrangements can be made, as necessary, to prevent transmission to others in the health care setting. In the absence of fever or respiratory symptoms, they need not limit their activities outside the home.</p></sec><sec id="cesec130"><title>Hospital Setting</title><p id="para800">Patients who require hospitalization should be admitted to a negative pressure, specially ventilated room. Visitors should be discouraged; the number of HCWs involved in the patient's care should be limited. All HCWs should use personal protective equipment appropriate for standard, contact, and airborne precautions (ie, hand hygiene, gown, gloves, and N-95 respirator) in addition to eye protection while caring for these patients. Procedures that result in coughing and aerosolization of respiratory secretions should be avoided. If bronchoscopy is considered essential for patient care, it should be performed by experienced personnel using maximum infection control precautions (<xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Infection Control Precautions for Patients Hospitalized With Suspected/Probable SARS<xref rid="tbl3fn1" ref-type="table-fn">*</xref></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><list list-type="simple" id="celist140"><list-item id="celistitem390"><p id="para390">Place patient in a negative pressure, specially vented room</p></list-item><list-item id="celistitem400"><p id="para400">Maintain a log of all persons entering the patient's room</p></list-item><list-item id="celistitem410"><p id="para410">Restrict visitors as much as possible</p></list-item><list-item id="celistitem420"><p id="para420">Limit the number of hospital personnel caring for the patient</p></list-item><list-item id="celistitem430"><p id="para430">All health care workers entering the room should use a combination of contact (gowns, gloves, hand hygiene) and airborne (N-95 respirator) precautions and eye protection</p></list-item><list-item id="celistitem440"><p id="para440">Do not bring pens, hospital charts, etc, in and out of the patient's room</p></list-item><list-item id="celistitem450"><p id="para450">Minimize air turbulence when changing linens</p></list-item><list-item id="celistitem460"><p id="para460">Clean surfaces in the room carefully and frequently with EPA-registered hospital-grade disinfectant</p></list-item><list-item id="celistitem470"><p id="para470">Limit cough-inducing procedures (sputum induction, administration of nebulized medications, suctioning, bronchoscopy)</p></list-item><list-item id="celistitem480"><p id="para480">Avoid use of noninvasive positive pressure ventilation (eg, CPAP, BiPAP)</p></list-item><list-item id="celistitem490"><p id="para490">For patients receiving mechanical ventilation, use closed-suctioning devices, HEPA filtration on exhalation valve port</p></list-item><list-item id="celistitem500"><p id="para500">Educate personnel involved in the care of these patients to be vigilant for symptoms of SARS for 10 days after contact with the patient</p></list-item><list-item id="celistitem510"><p id="para510">Quarantine personnel with unprotected contact with a SARS patient during an aerosol-generating procedure</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn id="tbl3fn1"><label>*</label><p>BiPAP = biphasic positive airway pressure; CPAP = continuous positive airway pressure; EPA = Environmental Protection Agency; HEPA = high-efficiency particulate air; SARS = severe acute respiratory syndrome.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="cesec140"><title>MANAGING HCW EXPOSURE</title><p id="para810">An important feature of the SARS outbreaks in Canada, Singapore, and Hong Kong has been the fact that several HCWs have developed SARS after caring for patients with SARS. Transmission to HCWs appears to have occurred after close, unprotected contact with symptomatic individuals. This has placed additional strain on health care systems that have already been stressed by outbreaks of SARS.</p><p id="para820">Active surveillance for fever and respiratory symptoms (eg, daily screening) should be conducted in HCWs with unprotected exposure for 10 days after the exposure, including checking the temperature when the employee reports to work and taking a history of respiratory symptoms. Workers with unprotected exposure who develop fever and/or respiratory symptoms should not come to work; they should stay home and report symptoms to infection control or the employee health service immediately. Health care workers with unprotected exposure during aerosolgenerating procedures (intubation, suctioning, bronchos-copy, etc) should be quarantined for a 10-day period at home because these procedures pose a higher risk of disease transmission.</p></sec><sec id="cesec150"><title>CONCLUSION</title><p id="para830">Case definitions of SARS are currently based on the presence of epidemiological risk factors (close contact with patients with SARS or travel to SARS-affected areas) and a combination of fever and respiratory symptoms, with or without chest radiographic changes. However, if SARS spreads into the general population, our ability to distinguish it from other community-acquired pneumonias based on such epidemiological linkages will fail. If this happens, SARS will need to be considered in the differential diagnosis of any community-acquired or nosocomial pneumonia. A “typical” history, suggestive laboratory values, and failure to respond to conventional antibiotics should raise suspicion. Diagnostic tests will be crucial in the future both to ensure that patients are isolated rapidly and to provide appropriate therapy.</p><p id="para840">SARS has resulted in important challenges for the medical community. In affected areas, policies are changing daily as more information about the virus and the disease is obtained.</p><p id="para850">The resurgence of cases in Toronto in early May 2003 shows the difficulty of maintaining control over a new disease characterized by many puzzling epidemiological and clinical features. The continued alertness of Singapore, which most recently broke the chain of SARS transmission, shows the importance of maintaining a high level of vigilance and preparedness to ensure that a single imported case does not reignite an outbreak. Currently, control depends on prompt detection and isolation of cases, good infection control in hospitals, and the tracing and quarantine of contacts.</p></sec></body><back><ref-list id="bibl10"><title>REFERENCES</title><ref id="bib1"><label>1</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><article-title>Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sarscountry/2003_04_23/en">Available at: www.who.int/csr/sarscountry/2003_04_23/en</ext-link><comment>Accessibility verified June 3, 2003.</comment></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Preliminary clinical description of severe acute respiratory syndrome</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>52</volume><year>2003</year><fpage>255</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">12680522</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Updated interim U.S. case definition of severe acute respiratory syndrome (SARS)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/sars/casedefinition.htm">Available at: www.cdc.gov/ncidod/sars/casedefinition.htm</ext-link><comment>Accessibility verified June 5, 2003.</comment></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Updated interim surveillance case definition for severe acute respiratory syndrome (SARS)—United States, April 29, 2003</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>52</volume><year>2003</year><fpage>391</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">12765204</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poutanen</surname><given-names>SM</given-names></name><name><surname>Low</surname><given-names>DE</given-names></name><name><surname>Henry</surname><given-names>B</given-names></name></person-group><article-title>Identification of severe acute respiratory syndrome in Canada</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1995</fpage><lpage>2005</lpage><pub-id pub-id-type="pmid">12671061</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>L-Y</given-names></name><name><surname>Lee</surname><given-names>C-C</given-names></name><name><surname>Green</surname><given-names>JA</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. <italic>Emerg Infect Dis</italic> [serial online]</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/EID/vol9no6/03-0264.htm">Available at: www.cdc.gov/ncidod/EID/vol9no6/03-0264.htm</ext-link><year>June 2003</year><comment>Accessibility verified June 4, 2003.</comment></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>CM</given-names></name><name><surname>Matukas</surname><given-names>LM</given-names></name><name><surname>Tomlinson</surname><given-names>GA</given-names></name></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>JAMA</source><volume>289</volume><year>2003</year><fpage>2801</fpage><lpage>2809</lpage><ext-link ext-link-type="uri" xlink:href="http://jama.ama-assn.org/cgi/search?fulltext=greater+toronto+area">Available at: http://jama.ama-assn.org/cgi/search?fulltext=greater+toronto+area</ext-link><comment>Accessibility verified June 4, 2003.</comment><pub-id pub-id-type="pmid">12734147</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VCC</given-names></name><name><surname>HKU/UCH SARS Study Group</surname></name></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. <italic>Lancet</italic> [serial online]</article-title><ext-link ext-link-type="uri" xlink:href="http://image.thelancet.com/extras/03art4432web.pdf">Available at: http://image.thelancet.com/extras/03art4432web.pdf</ext-link><year>May 2003</year><comment>Accessibility verified June 5, 2003.</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Hon</surname><given-names>KLE</given-names></name><name><surname>Leung</surname><given-names>CW</given-names></name><name><surname>Cheng</surname><given-names>WTF</given-names></name></person-group><article-title>Clinical presentations and outcome of severe acute respiratory syndrome in children. <italic>Lancet</italic> [serial online]</article-title><ext-link ext-link-type="uri" xlink:href="http://image.thelancet.com/extras/03let4127web.pdf">Available at: http://image.thelancet.com/extras/03let4127web.pdf</ext-link><year>April 2003</year><comment>Accessibility verified June 4, 2003.</comment></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name></person-group><article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1986</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">12682352</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name></person-group><article-title>Coronavirus as a possible cause of severe acute respiratory syndrome</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12711465</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">12690091</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Erdman</surname><given-names>D</given-names></name><name><surname>Goldsmith</surname><given-names>CS</given-names></name></person-group><article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1953</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">12690092</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Astell</surname><given-names>CR</given-names></name></person-group><article-title>The genome sequence of the SARS-associated coronavirus</article-title><source>Science Mag [serial on-line]</source><volume>300</volume><year>2003</year><fpage>1399</fpage><lpage>1404</lpage><ext-link ext-link-type="uri" xlink:href="http://www.sciencemag.org/cgi/content/abstract/1085953v1">Available at: www.sciencemag.org/cgi/content/abstract/1085953v1</ext-link><comment>Accessibility verified June 4, 2003.</comment></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rota</surname><given-names>PA</given-names></name><name><surname>Oberste</surname><given-names>MS</given-names></name><name><surname>Monroe</surname><given-names>SS</given-names></name></person-group><article-title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</article-title><source>Science Mag [serial online]</source><volume>300</volume><year>2003</year><fpage>1394</fpage><lpage>1399</lpage><ext-link ext-link-type="uri" xlink:href="http://www.sciencemag.org/cgi/content/abstract/1085952v1">Available at: www.sciencemag.org/cgi/content/abstract/1085952v1</ext-link><comment>Accessibility verified June 4, 2003.</comment></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><article-title>First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network</article-title><ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/survival_2003_05_04/en/">Available at: www.who.int/csr/sars/survival_2003_05_04/en/</ext-link><comment>Accessibility verified June 4, 2003.</comment></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Severe acute respiratory syndrome—Singapore, 2003</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>52</volume><year>2003</year><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">12807088</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Guidelines for collection of specimens from potential cases of SARS</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/sars/specimen_collection_sars2.htm">Available at: www.cdc.gov/ncidod/sars/specimen_collection_sars2.htm</ext-link><comment>Accessibility verified June 3, 2003.</comment></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Interim laboratory biosafety guidelines for handling and processing specimens associated with severe acute respiratory syndrome (SARS)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/sars/sarslabguide.htm">Available at: www.cdc.gov/ncidod/sars/sarslabguide.htm</ext-link><comment>Accessibility verified June 3, 2003.</comment></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>LK</given-names></name><name><surname>Lau</surname><given-names>AC</given-names></name><name><surname>Yam</surname><given-names>LY</given-names></name></person-group><article-title>Development of a standard treatment protocol for severe acute respiratory syndrome</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1615</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">12747883</pub-id></element-citation></ref></ref-list><sec sec-type="exam-questions"><sec id="cesec160"><title>Questions About SARS</title><p content-type="question"><list list-content="QandA" list-type="simple" id="celist150"><list-item id="celistitem520"><label>1.</label><p content-type="question">In which <underline><italic>one</italic></underline> of the following countries did the <underline><italic>first</italic></underline> cases of SARS seem to occur?
<list list-type="simple" id="celist160"><list-item id="celistitem530"><label>a.</label><p id="para880">United States</p></list-item><list-item id="celistitem540"><label>b.</label><p id="para890">Vietnam</p></list-item><list-item id="celistitem550"><label>c.</label><p id="para900">China</p></list-item><list-item id="celistitem560"><label>d.</label><p id="para910">Thailand</p></list-item><list-item id="celistitem570"><label>e.</label><p id="para920">Singapore</p></list-item></list></p></list-item><list-item id="celistitem580"><label>2.</label><p content-type="question">Which <underline><italic>one</italic></underline> of the following is the <underline><italic>etiologic</italic></underline> agent of SARS?
<list list-type="simple" id="celist170"><list-item id="celistitem590"><label>a.</label><p id="para940">A novel coronavirus</p></list-item><list-item id="celistitem600"><label>b.</label><p id="para950"><italic>Paramyxovirus</italic></p></list-item><list-item id="celistitem610"><label>c.</label><p id="para960">Influenza</p></list-item><list-item id="celistitem620"><label>d.</label><p id="para970">Avian influenza</p></list-item><list-item id="celistitem630"><label>e.</label><p id="para980">Resistant pneumococcus</p></list-item></list></p></list-item><list-item id="celistitem640"><label>3.</label><p content-type="question">Which <underline><italic>one</italic></underline> of the following patients would fit the CDC case definition for <underline><italic>probable</italic></underline> SARS?
<list list-type="simple" id="celist180"><list-item id="celistitem650"><label>a.</label><p id="para1000">A 45-year-old executive with a fever of 39°C (102°F), myalgias, dry cough, and a patchy left lower lobe infiltrate 5 days after returning from a business trip to Beijing</p></list-item><list-item id="celistitem660"><label>b.</label><p id="para1010">A 50-year-old male smoker with severe chronic obstructive pulmonary disease who presents with cough, greenish sputum, and left lower lobe consolidation 5 days after returning from a 2-week vacation with his grandchildren at Walt Disney World in Florida</p></list-item><list-item id="celistitem670"><label>c.</label><p id="para1020">A 35-year-old woman with a fever of 39°C, myalgias, dry cough, and normal findings on a chest x-ray film who returned from China 5 days ago with her adopted infant</p></list-item><list-item id="celistitem680"><label>d.</label><p id="para1030">A 40-year-old recent immigrant to the United States who presents with a 2-month history of cough productive of blood-streaked sputum, low-grade fever (maximum 37.8°C [100°F]), and progressive weight loss</p></list-item><list-item id="celistitem690"><label>e.</label><p id="para1040">A 60-year-old man with an ejection fraction of 20% who presents with shortness of breath, orthopnea, bilateral pulmonary infiltrates, and no fever 7 days after returning from Singapore</p></list-item></list></p></list-item><list-item id="celistitem700"><label>4.</label><p content-type="question">Which <underline><italic>one</italic></underline> of the following infection control precautions is <underline><italic>not</italic></underline> recommended by the CDC for possible cases of SARS in the hospital setting?
<list list-type="simple" id="celist190"><list-item id="celistitem710"><label>a.</label><p id="para1060">Airborne isolation</p></list-item><list-item id="celistitem720"><label>b.</label><p id="para1070">Droplet isolation</p></list-item><list-item id="celistitem730"><label>c.</label><p id="para1080">Use of gloves, gowns, good hand hygiene, and eye protection by health care personnel</p></list-item><list-item id="celistitem740"><label>d.</label><p id="para1090">Quarantine of the physician who performed bronchoscopy on the patient before the diagnosis of SARS was considered and infection control measures instituted</p></list-item><list-item id="celistitem750"><label>e.</label><p id="para1100">Mandatory quarantine of the patient's family even though they have no symptoms</p></list-item></list></p></list-item><list-item id="celistitem760"><label>5.</label><p content-type="question">Which <underline><italic>one</italic></underline> of the following statements regarding SARS is <underline><italic>false</italic></underline>?
<list list-type="simple" id="celist200"><list-item id="celistitem770"><label>a.</label><p id="para1120">A fever higher than 38°C (100.4°F) is necessary to fit the current CDC case definition</p></list-item><list-item id="celistitem780"><label>b.</label><p id="para1130">Nonproductive cough is frequently a presenting symptom</p></list-item><list-item id="celistitem790"><label>c.</label><p id="para1140">All patients who may have SARS must be admitted to a hospital</p></list-item><list-item id="celistitem800"><label>d.</label><p id="para1150">SARS may be less severe in children</p></list-item><list-item id="celistitem810"><label>e.</label><p id="para1160">Some patients with SARS may have a biphasic or triphasic illness</p></list-item></list></p></list-item></list></p></sec></sec><sec sec-type="exam-answers"><sec id="cesec170"><title> </title><p id="para1170">Correct answers:
<list list-type="simple" id="celist210"><list-item id="celistitem820"><label>1.</label><p id="para1180"><italic>c</italic>,</p></list-item><list-item id="celistitem830"><label>2.</label><p id="para1190"><italic>a</italic>,</p></list-item><list-item id="celistitem840"><label>3.</label><p id="para1200"><italic>a</italic>,</p></list-item><list-item id="celistitem850"><label>4.</label><p id="para1210"><italic>e</italic>,</p></list-item><list-item id="celistitem860"><label>5.</label><p id="para1220"><italic>c</italic></p></list-item></list></p></sec></sec><fn-group><fn id="d32e674"><p>A question-and-answer section appears at the end of this article.</p></fn></fn-group></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000B14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7094524
|texte= SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:12839084" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |